bind in Biological Technology

Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results

... diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevat...

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

...ones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosom...

Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT

... diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevat...

Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate

...eptide Constructs." Allowed claims cover a family of cyclic compounds that bind to natriuretic peptide receptor A (NPRA), including PL-3994, Palatin's lead... pharmacokinetic properties. These are the only drugs we are aware of that bind to NPRA and are suitable for subcutaneous administration, with the possibil...

Amicus Therapeutics Announces Second Quarter 2009 Financial Results Release Date

...ones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosom...

NYU physicists find way to explore microscopic systems through holographic video

... pharmaceuticals, stick together. One approach, called a "bead-based assay," creates micrometer-scale beads whose surfaces have active groups that bind to the target molecule. Because of their small size, the challenge for researchers is to determine if these beads actually stick to the target molecul...

New method may accelerate drug discovery for difficult diseases like Parkinson's

... proteins that occur at these surfaces. Cyclic peptides have the ability to bind where traditional drugs cannot, allowing for the identification of previous...cluding molecules that oxidize or reduce other molecules and molecules that bind to metals. Interestingly, there are already links between Parkinson's a...

Stem cells' 'suspended' state preserved by key step, scientists report

...l technique of RNA interference, or RNAi, to screen this gene and 40 other candidate genes. (RNAi is a naturally occurring process in which small RNAs bind to other RNAs to increase or decrease their activity.) In this case, the scientists used the technique to silence Chd1. When they did so, embryonic st...

High-Tech 'Smart' Face Mask Helps Hong Kong Families Combat Swine Flu

..., then quickly DESTROYS them by disrupting their surfaces (viruses) and cell walls (bacteria). Many viruses, including influenza viruses, are known to bind to a terminal sialic acid residue on the surface of the human cell membrane. The binding agent in the BioFriend(TM) textile mimics the binding action ...

Light sensor breakthrough could enhance digital cameras

... laptops suffer from noise and grainy images as a result of the small number excitons. "Multi-exciton generation breaks the conventional rules that bind traditional semiconductor devices," says Sargent. "This finding shows that it's more than a fascinating concept: the tangible benefits of multiple exc...

Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

...t links a radioactive isotope to a targeted monoclonal antibody designed to bind to the DNA histone complex that is exposed by dead and dying cells found at the center of solid tumors. Cotara's targeting mechanism enables it to bind to the dying tumor cells, delivering its radioactive payload to the adjacen...

Cynvec to Present at The 2009 New York Venture Summit

...vo efficacy delivering a variety of cytokines directly to tumor sites. Additionally, a screening program is underway to identify small molecules that bind to the laminin receptor, which is implicated in Alzheimer's disease, multiple sclerosis and Parkinson's. Further information on Cynvec can be found a...

'Designer molecules' being developed to fight disease

...ikha Sharma in Dr Nick Brindle's group in Department of Cardiovascular Sciences aims to allow researchers to rapidly make 'designer proteins' that can bind to disease causing molecules in the body. Shikha Sharma said "There are millions of different proteins that are involved in carrying out numerous ...

New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance

...lose precious treatment time potentially better spent on a different drug." HIV coreceptor tropism refers to the preference of strains of HIV to bind to, activate and infect cells, promoting disease progression, based on the type of coreceptor on the cell's surface. The newest class of antiretrovir...

Australia: Face Mask That Kills Swine Flu Readied for Australian Pandemic Fight

...y attach, then DESTROYS them by disrupting their surfaces (viruses) and cell walls (bacteria). Many viruses, including influenza viruses, are known to bind to a terminal sialic acid residue on the surface of the human cell membrane. The binding agent in the BioFriend(TM) textile mimics the binding action ...

Monsanto, BASF Scientists Disclose Discovery of Gene Conferring Drought Tolerance in Corn Plants

...lerant corn contains the cspB gene, from Bacillus subtilis . CspB codes for an RNA chaperone, which are commonly occurring protein molecules that bind to RNAs and facilitate their function. The gene was first identified in bacteria subjected to cold stress conditions and further research has demonstr...

Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients

... diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevat...

Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry

...vo efficacy delivering a variety of cytokines directly to tumor sites. Additionally, a screening program is underway to identify small molecules that bind to the laminin receptor, which is implicated in Alzheimer's disease, multiple sclerosis and Parkinson's. Further information on Cynvec can be found a...

Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer

...g diseases, including renal disease and cancer. Keryx is developing Zerenex(TM)(ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevat...

Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology

...g diseases, including renal disease and cancer. Keryx is developing Zerenex(TM)(ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevat...

YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS

... YM BioSciences. "These data demonstrate that nimotuzumab is predisposed to bind to cancerous cells with high levels of EGFR on their surface while ignoring... EGFR levels. For the competing drugs, binding is indiscriminate since they bind to low levels of EGFR and, as a result, these products cause severe toxicit...

Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT

... diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevat...

Amicus Therapeutics to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference on May 13, 2009

...ones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosom...

Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting

... of ER expression by the histone deacetylase inhibitor, followed by CYP1A1 induction and subsequent AFP metabolism into active species that covalently bind to DNA in these cancer cells and cause specific cell death. Dr. Burger said the findings offer particular hope to those women battling triple-n...

Amicus Therapeutics Announces First Quarter 2009 Financial Results Release Date

...ones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosom...

Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer

... diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated ...

Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting

...es against B-cell lymphoma cells in vitro . The CD79BxDR SCORPION can bind to two different targets: CD79B, a lineage-restricted component of the B-ce...MIP(TM)) proteins or monoclonal antibodies against the same target, but can bind both targets simultaneously. Results showed the CD79BxDR SCORPION molecule ...

Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research

...ng diseases, including renal disease and cancer. We are developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated ...

AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies

...rding to several studies presented at the American Association of Cancer Research (AACR) 100th Annual Meeting this past weekend. DXL625 is designed to bind CD20, a protein receptor expressed on normal B cells and over-expressed on cancerous B cells. InNexus has previously announced that the United ...

Cynvec to Present at New York Biotechnology Association 18th Annual Meeting

...ivo efficacy delivering a variety of cytokines directly to tumor sites. Additionally, a screening program is underway to identify small molecules that bind to the laminin receptor, which is implicated in Alzheimer's disease, multiple sclerosis and Parkinson's. Further information on Cynvec can be found a...

University of Maryland Announces Finalists for $75K Business Plan Competition

...in the Biotechnology Category include: Callinix : provides a microfluidic, drug-screening test bed using proprietary technology to bind cells and commercially relevant biological components, providing a cheaper and faster alternative to traditional well-plate methods. The Callinix test...

SeqWright to Invest in LaserGen's Novel Lightning Terminators(TM)

... In kinetic terms, Lightning Terminators(TM) are more efficient than natural nucleotides, a measure of how fast they are added by and how well they bind to DNA polymerase. Simply stated, Lightning Terminators(TM) are better than nature. All reversible terminators required a cleavage step to remove ...

Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth

...n animals, even in the presence of high levels of soluble CEA. "Our new publication demonstrates not only that BiTE antibodies can be designed to bind to well established target antigens of conventional monoclonal antibodies, but also that BiTE antibodies have features that improve on the properties ...

Fitting pieces for biosensors

...onmental analysis because their characteristics enable them to identify and bind target molecules as surely as a key fits a lock. In a new book, researchers...ds and have a three-dimensional structure that enables them to identify and bind certain target molecules. These binding abilities allow, for instance, trac...

New security and medical sensor devices made possible by metallic nanostructures

...en created. The device could be tailored to detect different chemicals by decorating the nanostructure surface with specific 'molecular traps' that bind the chosen target molecules. Once bound, the target molecules would change the colours that the device absorbs and scatters, alerting the sensor to th...

Researchers develop new way to see single RNA molecules inside living cells

...gned shine bright, are small and easy to assemble, bind rapidly to their targets, and can be imaged for ho...se probes is that they recognize RNA sequences and bind to them using the same base pairing most people ar...antangelo. "By adding only a few probes that would bind to a region of RNA, we gained the ability to disti...

MIT virus battery could power cars, electronic devices

...elves with iron phosphate, then grab hold of carbon nanotubes to create a network of highly conductive material. Because the viruses recognize and bind specifically to certain materials (carbon nanotubes in this case), each iron phosphate nanowire can be electrically "wired" to conducting carbon nanot...

BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth

...the unique ability to very precisely target the caries causing bacteria and bind exclusively to them, and clumping them. When aggregated and grouped togethe...entify the appropriate strain of Lactobacillus with the unique ability to bind specifically to Streptococcus mutans . "OrganoBalance's large proprietary ...

Amicus Therapeutics to Present at the 16th Annual Future Leaders in the Biotech Industry Conference

...nes for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysoso...

Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting

...ncreased risk of heart attack and stroke. Amigal is designed to selectively bind to and stabilize a-Gal A, which facilitates proper trafficking of the enzym...l chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and...